
    
      This was a randomised, double-blind, placebo-controlled, single dose, dose escalation study
      with 4 dosing cohorts. Within each cohort, 45 evaluable subjects were planned (36 subjects
      receiving M01ZH09, 9 receiving placebo).
    
  